MYC and neoplasm: Metabolic reprogramming in tumor cells profoundly reshapes the TME, promoting immunosuppression and therapeutic resistance.[24, 109, 170] Oncogenic signaling pathways such as PI3K/Akt/mTOR, MYC, and KRAS drive enhanced aerobic glycolysis, glutamine uptake, de novo lipid synthesis, and mitochondrial remodeling,[171] leading to aggressive consumption of nutrients like glucose, glutamine, serine, and arginine.